Needham & Company
View Older Stories
-
Vivus (VVUS) Revenue/Rx Improving, Needham & Company Notes
-
Vivus (VVUS) Qsymia Numbers Lowered at Needham & Company
-
Vivus, Inc. (VVUS) to Present at 13th Annual Needham Healthcare Conference
-
Vivus (VVUS) Qsymia Sales Lackluster and Partner Continues to be a Challenge: Needham & Company
-
Needham & Company Downgrades Vivus (VVUS) to Hold; Sees Disruption Following Settlement
-
VIVUS (VVUS) to Report Q1 Results May 8th; Focus on Promotions vs. New Rx
-
VIVUS (VVUS) Plans to Present at Four Conferences Through End of May
-
Needham Sees Strong Start for Arena's (ARNA) Belviq in U.S.; European Approval Unlikely
-
Needham & Company Sees 2nd-Half Qsymia Ramp for Vivus (VVUS)
-
Despite Slow Launch, Vivus's (VVUS) Qsymia Still Has Blockbuster Potential
-
Needham & Company Cuts Numbers on VIVUS Inc. (VVUS) on Slower Qsymia Launch, Keeps Buy on Blockbuster Potential
-
Needham & Company Cuts Target on Vivus (VVUS), Adjusts Qsymia Estimates
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Expect Approval of Qnexa by the PDUFA Date
-
Notable Analyst Rating Changes 04/25: (JCP) (AAPL) (STM) Upgraded; (PGR) (CRDN) (WMT) Downgraded
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Qnexa PDUFA Date Extension Doesn't Change Our View
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Qnexa FDA Advisory Committee Meeting Preview
-
Needham & Company reiterates a 'Buy' on Vivus (VVUS); 2012 Preview - Qnexa and Avanafil FDA Decisions in April
-
Vivus (VVUS) Shares Fall on Data Results, Downgrades, Though One Firm Remains Optimistic
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); FORTRESS Results Announced
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); 3Q11 Review: Awaiting FORTRESS Results in December
-
Needham & Company Maintains a 'Buy' on Vivus (VVUS); Risks Around Topiramate/Phentermine are Manageable
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Retrospective Topiramate Study to be Underway Soon, with Results Likely in 4Q11
-
Morning Movers 04/04: (MSSR) (OREX) (VVUS) Higher; (AMIE) (DGW) Lower
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); 4Q10 Review. Management Guiding for Qnexa NDA Resubmission by YE11
-
Needham Sees QNEXA's FDA Issues Being Resolved with REMS, Post-Approval Studies; VIVUS (VVUS) Shares Down 15% Today
-
Morning Movers 01/21: ORCC, DNBK, GENE, WMG, PLCM, HUGH, ISRG, GMXR, SMOD Higher; ACOR, IPCI, VVUS, SYNA Lower
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); 1Q11 Preview
-
Needham & Company Reiterates a 'Buy' on Vivus (VVUS); Contrave FDA Advisory Committee Vote a Positive for Obesity Space, Qnexa, and Vivus
-
Unusual 11 Mid-Day Movers 10/29: FMR, MWW, EONC, VVUS, TNAV, CSTR Higher; NR, NUVA, SNBC, EXAS, GRRF Lower
-
Morning Movers 10/29: FMR, VVUS, MWW, CSTR, TNAV, PTEK, AXTI, EL Higher; NUVA, NR, AMAG, VLCM, TNCC, SNBC, EXAS Lower
-
Notable Analyst Rating Changes 10/29: MWW, VVUS, MS, LVS Upgraded; FSLR, MEOH, NUVA, AVP Downgraded
-
Unusual 11 Mid-Day Movers 07/16: LSBX, ARNA, AVII, CYPB, SCHW, TSLA Higher; VVUS, JST, ROIAK, OREX, PLCM Lower
-
Notable Analyst Rating Changes 07/16: GS, JPM, ARNA, ADM Upgraded; VVUS, BP, RBA, OREX Downgraded
-
Morning Movers 7/16: LSBX, ARNA, AVII Higher; VVUS, JST, VRNM, BIOF, VIDE, PLCM Lower
-
Needham & Company Downgrades VIVUS (VVUS) to Hold Based on Negative Qnexa FDA Advisory Committee Vote
-
Unusual 11 Mid-Day Movers 07/12: YRCW, PLA, HEW, IFLG, ENCO, LF Higher; BSDM, VVUS, CPRX, ONAV, AON Lower
-
Needham & Company Reiterates a 'Buy' on VIVUS Inc. (VVUS); We Remain Positively Inclined Ahead of FDA Panel
-
Morning Movers 5/7: SXE, NCT, NANO, CDII, COGO, WNC Higher; TRMA, INAP, CAMP, GXDX, POWR, HLIT, HANS Lower
-
Needham & Company Reiterates a 'Buy' on VIVUS Inc. (VVUS); Qnexa Program Remains on Track
-
Notable Analyst Rating Changes 04/27: PPDI, MRVL, TASR, CAVM Upgraded; AIG, HBAN, NWSA, ACN Downgraded
-
Notable Analyst Rating Changes 04/14: AIB, ERIC, MCD, CREE Upgraded; POT/MOS, TWC/DTV, DNDN, NOK Downgraded
-
Needham & Company Initiates Coverage on VIVUS Inc. (VVUS) with a Buy; Project a Positive Qnexa Advisory Committee Review and FDA Approval
-
Needham & Company Starts VIVUS (VVUS) at Buy
-
Notable Analyst Rating Changes 12/17: NWSA, UNM, LNC, PTV Upgraded; ADP, AEM, FGXI, OC Downgrades